Menu

NYU Halts Studies, Suspends Investigator

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

Jun 28, 2016
Bob Grant

WIKIMEDIA, EVERYONE'S IDLENew York University (NYU) School of Medicine has shuttered eight studies on an investigational drug to treat psychological trauma, according to documents obtained by The New York Times. The US Food and Drug Administration (FDA) conducted an investigation of the trials last year. In a letter to the studies’ principal investigator, Alexander Neumeister, FDA investigators wrote that the research was fraught with violations that “jeopardize subject safety and welfare, and raise concerns about the validity and integrity of the data collected at your site.”

The trials, which were sponsored by pharmaceutical firm Pfizer, aimed to test the efficaciousness of a drug—a fatty acid amide hydrolase (FAAH) inhibitor. One study involved people suffering from post-traumatic stress disorder (PTSD), among other conditions. FAAH inhibitors are meant to simulate the effects of marijuana.

According to the New York Times, NYU suspended Neumeister after learning of the FDA’s conclusions, which included alleging that the researcher failed to follow up in a timely fashion with patients who had received the drug, and that he had forged a colleague’s name on study reports. After confirming the research misconduct, NYU’s psychiatric department chairman Charles Marmar placed Neumeister on leave; Neumeister later resigned.

“I honestly believed I had the best qualified and among the most ethical researchers on the faculty” running these studies, Marmar told the New York Times. Neumeister’s lawyer, Georges Lederman, told the paper that “NYU has taken the position that those violations were more egregious than we believe they actually were.”

According to Marmar, NYU has discarded all data gathered from one of the trials, which recruited 50 participants, and is checking on their health.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.